Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 18M | 23M | 32M | 40M | 48M |
| Gross Profit | 6M | 6M | 10M | 22M | 25M |
| Operating Income | -3M | -8M | -4M | -7M | 14M |
| EBITDA | -3M | -7M | -3M | -6M | 14M |
| Net Income | -4M | -9M | -6M | -9M | 11M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$2.95
+1.37% today
1Y Change
-22.81%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Universe Pharmaceuticals Inc. (UPC) is a Healthcare stock with listed on NASDAQ. The stock last traded around $2.95 and down 22.8% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of -22.4%, EPS growth of +26.5%, a dividend yield of 0.0%. What stands out right now is revenue -22.4%, EPS +26.5%, free cash flow +45.3% with operating margin -16.3% and ROIC -4.5%. Valuation is more restrained than many high-expectation growth names at price/sales 0.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines UPC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
UPC
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
UPC Max Drawdown
-76.25%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for UPC and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$48.0M
+19.5% YoY
FY Net Income
$11.3M
+229.6% YoY
Free Cash Flow
-$15.6M
-1008.6% YoY
Revenue Growth
-22.4%
EPS Growth
+26.5%
Gross Margin
35.3%
Net Margin
-20.6%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 18M | 23M | 32M | 40M | 48M |
| Gross Profit | 6M | 6M | 10M | 22M | 25M |
| Operating Income | -3M | -8M | -4M | -7M | 14M |
| EBITDA | -3M | -7M | -3M | -6M | 14M |
| Net Income | -4M | -9M | -6M | -9M | 11M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 34M | 29M | 5M | 6M | 8M |
| Total Assets | 69M | 68M | 53M | 60M | 70M |
| Total Liabilities | 13M | 22M | 14M | 13M | 11M |
| Shareholder Equity | 56M | 46M | 40M | 46M | 59M |
| Total Debt | 9M | 8M | 5M | 4M | 4M |
| Net Debt | -24M | -22M | 197K | -2M | -4M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2M
-56.7% YoY
Capital Expenditures
14M
-14340.5% YoY
Free Cash Flow
16M
-1008.6% YoY
Key ratios
Gross Margin
35.3%
Operating Margin
-16.3%
Net Margin
-20.6%
ROE
-6.6%
Debt / Equity
0.16x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.